Atea Q3 net loss $31.2M (-$0.37/sh); COVID-19 Phase 3 fails, HCV topline Dec 2024

Atea Pharmaceuticals, Inc.

2024-Q3 EPS reported -$1.60

Net loss $31.2M ($0.37 diluted EPS) vs $33.1M loss ($0.40) YoY; cash $482.8M at Sept 30.
Phase 3 SUNRISE-3 COVID-19 trial missed primary endpoint; no regulatory path pursued.
Phase 2 HCV study (n=275) topline SVR12 results expected early Dec 2024; FDA End-of-Phase 2 meeting planned Q1 2025.
R&D spend $26.2M, down $2.0M YoY due to lower COVID spend offset by higher HCV costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.